Journal article
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities
K Garcia, AC Gingras, KF Harvey, MR Tanas
Trends in Cancer | CELL PRESS | Published : 2022
Abstract
The Hippo pathway is dysregulated in many different cancers, but point mutations in the pathway are rare. Transcriptional co-activator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP) fusion proteins have emerged in almost all major cancer types and represent the most common genetic mechanism by which the two transcriptional co-activators are activated. Given that the N termini of TAZ or YAP are fused to the C terminus of another transcriptional regulator, the resultant fusion proteins hyperactivate a TEAD transcription factor-based transcriptome. Recent advances show that the C-terminal fusion partners confer oncogenic properties to TAZ/YAP fusion proteins by recruiting epigene..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by a University of Iowa Sarcoma Multidisciplinary Oncology Group pilot award (M.R.T.), a grant from the Veterans Health Administration Merit Review Program 1 I01 BX003644-01 (M.R.T.), grants from the National Institutes of Health, National Cancer Institute 1 R01 CA237031-01A1 and 1 R01 CA237031-01A1S1 (M.R.T.), and an National Cancer Institute Core Grant P30 CA086862 (University of Iowa Holden Comprehensive Cancer Center). K.F.H. was supported by a National Health and Medical Research Council Senior Research Investigator Grant (APP1194467). A-C.G. was supported by the Canadian Institutes of Health Research (FDN 144301) and the Terry Fox Research Institute, and is the Tier1 Canada Research Chair in Functional Proteomics.